Data / Drug companies / Lannett Company, Inc.
Lannett Company, Inc.: 151 products in the FDA NDC directory, labeler code 0527
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Lannett Company, Inc. (labeler code 0527) lists 151 products in the FDA National Drug Code Directory, covering 50 finished drugs by generic name. By type: 151 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on January 12, 2026.
The request: Watch Lannett Company, Inc. (FDA labeler code 0527): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 0527
- Products in commercial distribution
- 151
- Packages
- 225
- Finished drugs by generic name
- 50
- Prescription products
- 151
- Over the counter products
- 0
- Controlled substance products
- Schedule II 52, Schedule III 2, Schedule IV 2
- Flagged as original packager
- 129 of 129 products that carry the flag
- Started marketing in the last 12 months
- 1
- Earliest marketing start
- September 30, 1974
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 127 | 84.1% |
| Authorized generics (NDA) | 18 | 11.9% |
| New drug applications (NDA) | 6 | 4% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 151 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 43 | 28.5% |
| Capsule, extended release | 30 | 19.9% |
| Capsule | 25 | 16.6% |
| Tablet, film coated | 19 | 12.6% |
| Tablet, extended release | 7 | 4.6% |
| Tablet, coated | 5 | 3.3% |
| Tablet, orally disintegrating | 4 | 2.6% |
| Solution | 3 | 2% |
| Tablet, film coated, extended release | 2 | 1.3% |
| Spray | 2 | 1.3% |
| Tablet, delayed release | 2 | 1.3% |
| Powder | 2 | 1.3% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Fluticasone Propionate and Salmeterol | 0527-6010 | Powder | Generic drugs (ANDA) | January 12, 2026 |
| Famotidine | 0527-5190 | Powder, for suspension | Generic drugs (ANDA) | June 2, 2025 |
| Fluticasone Propionate and Salmeterol | 0527-6011 | Powder | Generic drugs (ANDA) | November 29, 2024 |
| Metadate cd | 0527-6584 | Capsule, extended release | New drug applications (NDA) | February 22, 2024 |
| Metadate cd | 0527-6583 | Capsule, extended release | New drug applications (NDA) | February 22, 2024 |
| Metadate cd | 0527-6582 | Capsule, extended release | New drug applications (NDA) | February 22, 2024 |
| Metadate cd | 0527-6581 | Capsule, extended release | New drug applications (NDA) | February 22, 2024 |
| Metadate cd | 0527-6580 | Capsule, extended release | New drug applications (NDA) | February 22, 2024 |
| Metadate cd | 0527-6579 | Capsule, extended release | New drug applications (NDA) | February 22, 2024 |
| Prazosin | 0527-4182 | Capsule | Generic drugs (ANDA) | January 3, 2024 |
| Prazosin | 0527-4181 | Capsule | Generic drugs (ANDA) | January 3, 2024 |
| Prazosin | 0527-4180 | Capsule | Generic drugs (ANDA) | January 3, 2024 |
| Lisdexamfetamine Dimesylate | 0527-4667 | Capsule | Generic drugs (ANDA) | August 25, 2023 |
| Lisdexamfetamine Dimesylate | 0527-4666 | Capsule | Generic drugs (ANDA) | August 25, 2023 |
| Lisdexamfetamine Dimesylate | 0527-4665 | Capsule | Generic drugs (ANDA) | August 25, 2023 |
| Lisdexamfetamine Dimesylate | 0527-4664 | Capsule | Generic drugs (ANDA) | August 25, 2023 |
| Lisdexamfetamine Dimesylate | 0527-4663 | Capsule | Generic drugs (ANDA) | August 25, 2023 |
| Lisdexamfetamine Dimesylate | 0527-4662 | Capsule | Generic drugs (ANDA) | August 25, 2023 |
| Lisdexamfetamine Dimesylate | 0527-4661 | Capsule | Generic drugs (ANDA) | August 25, 2023 |
| Sevoflurane | 0527-6123 | Liquid | Generic drugs (ANDA) | August 18, 2023 |
| Oseltamivir Phosphate | 0527-5137 | Suspension | Generic drugs (ANDA) | July 13, 2023 |
| Mesalamine | 0527-3012 | Tablet, delayed release | Generic drugs (ANDA) | June 3, 2023 |
| Olanzapine | 0527-3164 | Tablet, orally disintegrating | Generic drugs (ANDA) | May 30, 2023 |
| Olanzapine | 0527-3163 | Tablet, orally disintegrating | Generic drugs (ANDA) | May 30, 2023 |
| Olanzapine | 0527-3162 | Tablet, orally disintegrating | Generic drugs (ANDA) | May 30, 2023 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.